Arisan Therapeutics Inc.
Carlsbad, CA
- UEI
- PYRKTQPNVJZ8
- CAGE
- 616D2
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 5825 Avenida Encinas #101, Carlsbad, CA 92008, USA
- Website
- arisanthera.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| To develop a therapeutic small molecule viral entry inhibitor as a medical countermeasure for filovirus infection. | National Institute of Allergy and Infectious Diseases | $2,933,547 | |
| To conduct non-clinical good laboratory practice (GLP) in vivo genotoxicity and reproductive toxicology and GLP… | National Institute of Allergy and Infectious Diseases | $3,692,037 | |
| Phase II - sbir topic CBD192-006 | ACC Aberdeen Proving Ground | $1,099,662 | |
| Phase II base period | ACC Aberdeen Proving Ground | $526,794 | |
| IND-enabling studies for arenavirus preclinical candidate - summary arenaviruses comprise a diverse family. Several… | National Institute of Allergy and Infectious Diseases | $11,312,244 |
About Arisan Therapeutics Inc.
Arisan Therapeutics Inc. is a corporate entity providing research and development services to U.S. federal agencies, primarily the Department of Health and Human Services and the Department of Defense. Through federal contracts, the company conducts non-clinical toxicology studies and provides research services associated with developing countermeasures against chemical and biological threats.
Arisan Therapeutics has been awarded over $5 million in federal contracts from HHS and DOD agencies since 2020. This includes a $3.7 million definitive contract from the National Institutes of Health to perform reproductive toxicology and Good Laboratory Practice toxicology studies. Additionally, Arisan was awarded a $1.1 million Phase II SBIR contract to conduct research and development supporting the Joint Program Executive Office for Chemical and Biological Defense. The company has also received Phase I and Phase II SBIR contracts from this DOD agency totaling over $790,000 to serve as a principal investigator and conduct pharmacokinetic and tolerability studies. The SBIR awards have been designated as total small business set asides.
Through a project grant from the NIH National Institute of Allergy and Infectious Diseases, Arisan Therapeutics was provided $7.1 million to complete IND-enabling and advanced nonclinical studies for a preclinical candidate oral entry inhibitor drug with demonstrated broad spectrum antiviral efficacy against arenaviruses. The project aims to develop a treatment for Lassa virus and other viral hemorrhagic fevers.
Quick answers
What is Arisan Therapeutics Inc.'s UEI?
Arisan Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is PYRKTQPNVJZ8.
What is Arisan Therapeutics Inc.'s CAGE code?
Arisan Therapeutics Inc.'s CAGE code is 616D2.
What is Arisan Therapeutics Inc.'s primary NAICS code?
Arisan Therapeutics Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Arisan Therapeutics Inc. located?
Arisan Therapeutics Inc.'s physical address in SAM.gov is 5825 Avenida Encinas #101, Carlsbad, CA 92008, USA.
Is Arisan Therapeutics Inc. registered in SAM.gov?
Yes. Arisan Therapeutics Inc.'s SAM.gov registration is active through December 18, 2026.
What is Arisan Therapeutics Inc.'s most recent federal award?
Arisan Therapeutics Inc.'s most recent federal contract award is To develop a therapeutic small molecule viral entry inhibitor as a medical countermeasure for filovirus infection (75N93026C00012), from National Institute of Allergy and Infectious Diseases, on August 3, 2026.
On GovTribe
See Arisan Therapeutics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors